Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leuke… (NCT01511575) | Clinical Trial Compass
CompletedNot Applicable
Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder
60 participantsStarted 2012-02
Plain-language summary
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn about changes that occur in RNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies RNA samples from patients with Down syndrome and acute myeloid leukemia or other transient myeloproliferative disorder.
Who can participate
Age range
3 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Patients with Down syndrome (DS) diagnosed with acute myeloid leukemia or transient myeloproliferative disorder
* Clinical samples obtained from patients enrolled on the COG AAML0431 and COG AAML08B1
PATIENT CHARACTERISTICS:
* Previously consented to biologic studies
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this study is focused on comparing gene expression in Down syndrome-related leukemia versus non-Down syndrome leukemia, how might the findings from this kind of biomarker research potentially affect how my child's or my own treatment is approached in the future?
2This trial is listed as completed — has my doctor seen or reviewed any published results from this study, and do those findings change anything about how DS-associated acute myeloid leukemia or transient myeloproliferative disorder is understood today?
3Since this was a biomarker study rather than a treatment trial, it wasn't testing a new drug or therapy directly — so is there a follow-up treatment trial that came out of research like this that might be worth discussing as a next step?
4Given that this study specifically looked at differences between Down syndrome and non-Down syndrome leukemia at the molecular level, does my doctor think those biological differences should influence which standard or experimental treatment options we consider?
5Because this was a research study measuring gene expression rather than comparing treatments, what does my doctor think is currently the best-supported treatment path for someone with Down syndrome and acute myeloid leukemia or transient myeloproliferative disorder based on what's known today?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Gene expression levels between DS AMKL and non-DS AMKL patients